Approvals and voucher sales secure the 2027 profit plan
- The FDA approved gene therapies GENGLYCOS and FAYUVI in late 2026.
- The company sold two priority review vouchers for $350 million to fund operations.
- Clinical trials for GTX-102 and UX701 failed, leading to program terminations.
- Ultragenyx cut its workforce by 20 percent to align costs with the remaining pipeline.
- Record Q2 2026 revenue reached $214 million, with Evkeeza sales up 50 percent.
A cleared financial runway meets a depleted pipeline
Ultragenyx transformed its business in late 2026. The FDA approved two major gene therapies, GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome. By selling the associated priority review vouchers for $350 million, management secured the balance sheet and cleared the path to their 2027 profitability target.
While the commercial side is winning, the clinical pipeline took a massive hit. The company terminated its GTX-102 program for Angelman syndrome after a Phase 3 failure and ended its UX701 program for Wilson disease due to poor efficacy. This forced a 20 percent workforce reduction to realign spending.
Finn's view acknowledges the sharply altered reality. The financial overhang is gone, and the company is no longer waiting on binary FDA decisions. However, with the late-stage pipeline hollowed out, the entire growth story now rests on executing the commercial launches of GENGLYCOS and FAYUVI without stumbling.
Small patient groups, high stakes
Ultragenyx finds, develops, and sells drugs for rare and ultra-rare diseases. These illnesses affect small patient groups, so each drug serves a limited number of people. The payoff comes from high prices and limited direct competition for these highly specialized treatments.
Money flows from product sales of Crysvita, Dojolvi, Evkeeza, Mepsevii, and now the newly approved GENGLYCOS and FAYUVI. Crysvita is the main revenue driver. Ultragenyx sells directly in some markets, like Latin America, and receives collaboration revenue from partners in North America and Europe.
The company expects to reach profitability in 2027. That timeline is now fully funded by the $350 million sale of priority review vouchers in October 2026. To protect this timeline after recent clinical failures, management cut 20 percent of the workforce to strictly control expenses.
The moat relies on specialized knowledge in finding rare disease patients and dealing with complex regulators. The weakness is the binary nature of clinical trials, where years of investment can vanish overnight when a drug fails a late-stage test.
What sells now, what could matter next
Crysvita
Crysvita treats X-linked hypophosphatemia and tumor-induced osteomalacia. It is the main revenue driver, contributing $156 million in Q2 2026.
GENGLYCOS
An FDA-approved gene therapy for glycogen storage disease type Ia. Commercial launch metrics in early 2027 are the next major focus.
FAYUVI
An FDA-approved gene therapy for Sanfilippo syndrome. Like GENGLYCOS, its initial launch trajectory will dictate near-term growth.
Evkeeza
Evkeeza treats homozygous familial hypercholesterolemia. It was the strongest commercial grower in Q2 2026, with sales up 50 percent year over year to $21 million.
Dojolvi
Dojolvi treats long-chain fatty acid oxidation disorders. It brought in $27 million in Q2 2026, though generic litigation remains a legal threat.
Mepsevii
Mepsevii treats MPS VII, a very rare genetic disease. It contributed $10 million in Q2 2026.
DTX301
A gene therapy for ornithine transcarbamylase deficiency. Phase 3 study enrollment is complete with data expected in the first half of 2027.
UX143
UX143 is being studied for osteogenesis imperfecta. Its Phase 3 trials failed, and the regulatory path forward remains uncertain and potentially expensive.
Q2 product mix leans heavily on Crysvita
The mix below uses Q2 2026 total revenue of $214 million. Crysvita accounted for $156 million, Dojolvi for $27 million, Evkeeza for $21 million, and Mepsevii for $10 million.
What could go wrong
Gene therapy launch execution
High impact · Medium oddsWith the late-stage pipeline gutted by recent clinical failures, all growth expectations sit on the commercial rollout of GENGLYCOS and FAYUVI. Any delay in activating treatment centers or enrolling patients will directly threaten the 2027 profitability plan.
Expanding Dojolvi generic challenges
Medium impact · Medium oddsSomerset and Sun Pharma filed ANDAs seeking approval for generic versions of Dojolvi. Ultragenyx filed patent infringement suits in response. An unfavorable legal outcome could pressure a product that contributes meaningful steady sales.
UX143 regulatory dead end
Medium impact · High oddsUX143 failed its Phase 3 endpoints in late 2025. The UK MHRA indicated a new randomized study is likely needed. If the FDA also demands a new trial instead of alternative fracture analyses, the program may become too expensive to salvage.
In one breath
What does Ultragenyx do?
Ultragenyx develops and sells treatments for rare and ultra-rare diseases. Its commercial drugs include Crysvita, Dojolvi, Evkeeza, Mepsevii, and newly approved gene therapies GENGLYCOS and FAYUVI.
Did Ultragenyx get FDA approval for its gene therapies?
Yes. The FDA approved GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome in August and September of 2026.
Is Ultragenyx profitable?
The company expects to reach profitability in 2027. This plan was recently secured when they sold two priority review vouchers for $350 million to fund their operations.
What happened to the Angelman syndrome drug?
The GTX-102 program for Angelman syndrome failed its Phase 3 clinical trial in late 2026. Ultragenyx terminated the program and cut 20 percent of its workforce to reduce costs.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Ultragenyx Pharmaceutical Inc. in Finn's Biotechnology industry ranking.

